For the period (end-31 March), GE HealthCare had revenues of $4.707 billion (4.272 billion euros) as reported, up 8% from the $4.343 billion (3.941 billion euros) produced in the first quarter of 2022. Organic revenue, however, reached $4.881 billion (4.430 billion euros), up 12%.
First-quarter net income was $372 million (338 million euros), down from $389 million (353 million euros) in the same period last year. Adjusted EBIT, however, was $664 million (603 million euros), compared with $599 million (544 million euros) in the first quarter a year ago.
On an individual segment basis, GE HealthCare's Imaging segment had revenues of $2.496 billion (2.266 billion euros), up 12% on an organic basis from the $2.311 billion (2.098 billion euros) reported in the first quarter of 2022. Growth was driven by MR and molecular imaging/CT due to fulfillment improvements in the company's supply chain, as well as by new product introductions.
Imaging EBIT dipped slightly, however, from $206 million (187 million euros) in the first quarter of 2022 to $191 million (173 million euros) this year. Planned investments and product mix outweighed higher volume, according to the firm. Looking ahead, GE HealthCare expects that the Imaging segment will experience stable demand for the rest of the year, boosted by a backlog in elective procedures, expansion of high-end diagnostic exams, and new therapies requiring precision image guidance, GE said.
Meanwhile, the Ultrasound segment generated revenues of $859 million (780 million euros), up 10% on an organic basis from the $815 million (740 million euros) turned in during the same period a year ago. The company highlighted strong organic revenue growth in cardiovascular, general imaging, and women's health products.
The Ultrasound segment had segment EBIT of $207 million (188 million euros), up from $192 million (174 million euros) in the first quarter of 2022. Profitability improved thanks to productivity, price, and volume, according to the vendor. GE HealthCare projects that the segment will be bolstered for the rest of 2023 by new product introductions and product localizations, we well as clinical innovation and improved efficiency.
As for GE HealthCare's Pharmaceutical Diagnostics segment, organic revenues reached $558 million (507 million euros) in the first quarter of 2023, up 19% from the $484 million (439 million euros) in revenue garnered during the first quarter last year. Growth was driven by price and volume, according to the company.
Segment EBIT was $155 million (141 million euros), compared with $138 million (125 million euros) a year ago. EBIT margin was down, however, due mainly to raw material inflation and investments, GE HealthCare said. The Pharmaceutical Diagnostics segment is expected to produce continued volume growth in 2023 as procedure volumes return to pre-COVID-19 levels, according to the firm. Furthermore, it is accelerating capacity expansion in order to meet increasing demand, GE Healthcare said.
In other financial developments, GE will be paying a cash dividend of $0.03 per share (0.027 euros per share) for the first quarter.
Copyright © 2023 AuntMinnieEurope.com